Impact of Ixekizumab on Work Productivity in Patients with Ankylosing Spondylitis: Results from the COAST-V and COAST-W Trials at 52 Weeks

Table 1 Baseline characteristics for biologic disease-modifying antirheumatic drug-naïve (COAST-V study) and tumor necrosis factor inhibitor inhibitor-experienced (COAST-W study) patients

Baseline characteristics	Patient groups
Baseline characteristics	bDMARD-naïve (COAST-V study) (N = 341)	TNFi-experienced (COAST-W study) (N = 316)
Age, years	41.7 (11.7)^b	46.1 (12.4)
Male, n (%)	276 (81.2)^b	253 (80.1)
Weight, kg	78.1 (15.8)^b	83.2 (18.7)
Duration of r-axSpA symptoms, years	16.0 (10.3)^b	18.4 (11.1)
Time since r-axSpA diagnosis, years	7.7 (8.4)^b	11.6 (9.1)
C-reactive protein level, mg/L	13.5 (17.1)^b	17.8 (26.6)
Therapy, n (%)
Current cDMARD use (including MTX)	125 (36.8)^b	86 (27.2)
Current MTX use	29 (8.5)^b	41 (13.0)
Current SSZ use	97 (28.5)^b	46 (14.6)
IR to 1 TNFi	–	205 (65.1)^e
IR to 2 TNFi	–	78 (24.8)^e
Intolerance to TNFi	–	32 (10.2)^e
ASDAS	3.8 (0.8)^b	4.1 (0.8)
Disease activity and pain
Patient global (disease activity) NRS	7.0 (1.6)^b	7.9 (1.7)
Spinal pain NRS	7.2 (1.5)^b	7.9 (1.5)
Spinal pain at night NRS	7.0 (1.6)^b	7.7 (1.7)
Inflammation (BASDAI questions 5 and 6)	6.7 (1.7)^b	7.3 (1.7)
Fatigue (fatigue NRS)	6.8 (1.7)^b	7.3 (1.8)
Sleep (JSEQ)	8.2 (5.2)^b	10.4 (5.6)
Reported part-time or full-time paid work, n (%)	252 ( 74.1)^b	182 (57.6)
Work productivity (WPAI-SpA)
Absenteeism^a	10.9 (23.5)^c	18.1 (27.2)^f
Presenteeism^a	56.8 (21.0)^d	60.7 ( 20.7)^g
Overall work impairment score^a	58.7 (22.0)^d	64.4 (21.5)^g
Activity impairment	60.3 (19.8)^b	70.7 (19.3)

Data are presented as the mean with the standard deviation (SD) in parentheses, unless otherwise stated
ASDAS Ankylosing Spondylitis Disease Activity Score, BASDAI Bath Ankylosing Spondylitis Disease Activity Index, cDMARD conventional disease-modifying antirheumatic drug, IR inadequate responder, JSEQ Jenkins Sleep Evaluation Questionnaire, MTX methotrexate, N number of patients in the analysis category, NRS numeric rating score, r-axSpA radiographic axial spondyloarthritis, SSZ sulfasalazine, TNFi tumor necrosis factor inhibitor, WPAI-SpA Work Productivity and Activity Impairment Questionnaire for Ankylosing Spondylitis
^aAbsenteeism, presenteeism, and overall work impairment were measured in patients reporting part- or full-time work
^bN = 340
^cN = 245
^dN = 234
^eN = 315
^fN = 167
^gN = 157